| Frequency of BCR-ABL gene mutations in Polish patients with chronic myeloid leukemia treated with imatinib: a final report of the MAPTEST study. | |
| | |
MedLine Citation:
|
PMID: 20010464 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
INTRODUCTION: The presence of BCR-ABL oncogene mutations in patients with chronic myeloid leukemia (CML) may be responsible for the failure of tyrosine kinase inhibitor treatment. OBJECTIVES: The aim of the study was to evaluate the frequency of BCR-ABL gene mutations in patients with CML (the MAPTEST study) treated with imatinib (IM). PATIENTS AND METHODS: Direct sequencing analysis of BCR-ABL gene was performed in 92 patients treated with IM for more than 3 months. The mean time of IM treatment was 18 months. At the time of the analysis, 75 patients were in the first chronic phase (CP), 4 in the second CP, 5 in the acceleration and 8 in the blastic phase. Fifty-seven patients (62%) were treated with IM at a daily dose of 400 mg and 35 patients with higher doses (600 or 800 mg daily). Inclusion criteria were based on the European Leukemia Net definitions for failure and suboptimal response to IM. RESULTS: Twelve mutations were detected in 11 of 92 patients, including 4 mutations (36.7%) diagnosed during CP, 3 (27.3%) in acceleration, and 4 (36.7%) in blast crisis. In 1 patient with lymphoid blast crisis of CML coexisting F359V and Y253F mutations were detected. In the whole group mutations were detected in 2 of 5 patients (40%) with primary resistance (M351T, F359V + Y253F) and in 9 of 87 patients (10.3%) (E255K, T315I-3x, M351T, E355G, F359V-2x) with acquired resistance to IM. CONCLUSIONS: The study confirmed the usefulness of BCR-ABL gene mutation screening in patients with CML resistant to IM therapy. |
| | |
Authors:
|
Krzysztof Lewandowski; Krzysztof Warzocha; Andrzej Hellmann; Aleksander Skotnicki; Witold Prejzner; Kajetana Foryciarz; Tomasz Sacha; Micha? Gniot; Miros?aw Majewski; Iwona Solarska; Grazyna Nowak; Bartosz Wasag; Miko?aj Kobelski; Cezary Scibiorski; Marek Siemiatkowski; Maria Lewandowska; Mieczys?aw Komarnicki |
Related Documents
:
|
16675574 - Minimal residual disease in hairy cell leukemia patients assessed by clone-specific pol... 6689734 - Alpha interferon for induction of remission in hairy-cell leukemia. 6381384 - Autologous bone marrow transplantation for acute leukemia using transplant chemopurifie... 17684634 - The investigation of parvovirus b19 infection in patients with haematological disorders... 22082534 - Dilated dysplastic vestibule: a new computed tomographic finding in patients with large... 17715084 - Liver volume variation in patients with virus-induced cirrhosis: findings on mdct. |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Polskie Archiwum Medycyny Wewn?trznej Volume: 119 ISSN: 1897-9483 ISO Abbreviation: Pol. Arch. Med. Wewn. Publication Date: 2009 Dec |
Date Detail:
|
Created Date: 2009-12-17 Completed Date: 2010-05-06 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0401225 Medline TA: Pol Arch Med Wewn Country: Poland |
Other Details:
|
Languages: eng Pagination: 789-94 Citation Subset: IM |
Affiliation:
|
Department of Hematology, Poznan University of Medical Sciences, Pozna?, Poland. krzysztof.lewandowski@sk1.am.poznan.pl |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Antineoplastic Agents / therapeutic use* Chromatography, High Pressure Liquid DNA Mutational Analysis Dose-Response Relationship, Drug Drug Resistance, Neoplasm / genetics* Female Fusion Proteins, bcr-abl / genetics* Gene Expression Regulation, Leukemic Humans Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*, genetics* Male Middle Aged Neoplasm Staging Piperazines / therapeutic use* Poland Protein Kinase Inhibitors / therapeutic use* Pyrimidines / therapeutic use* Treatment Outcome Young Adult |
| Chemical | |
Reg. No./Substance:
|
0/Antineoplastic Agents; 0/Fusion Proteins, bcr-abl; 0/Piperazines; 0/Protein Kinase Inhibitors; 0/Pyrimidines; 152459-95-5/imatinib |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Superoxide anion production by bronchoalveolar lavage cells in relation to cellular composition and ...
Next Document: Persistent pain in the older adult: what should we do now in light of the 2009 American Geriatrics S...